WS
ASND icon

Wedbush Securities’s Ascendis Pharma A/S ASND Stock Holding History

Wedbush Securities’s Portfolio ASND Stock Details ASND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-2,413
Closed -$304K – 1236
2023
Q4 		$304K Buy
+2,413
New +$241K 0.01% 756

Other funds holding ASND

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Wedbush Securities's ASND Position: Q1 2024 in Review

Wedbush Securities sold out of Ascendis Pharma A/S (ASND) in Q1 2024, closing a stake of 2,413 shares — an estimated $304K sold.

Wedbush Securities first reported a position in ASND in Q4 2023 and held it in 1 quarter. The position peaked at $304K in Q4 2023. 189 funds tracked by Wall St. Rank hold ASND as of Q1 2024.

  • Wedbush Securities reported no remaining Ascendis Pharma A/S position as of Q1 2024 after selling out during the quarter.
  • Wedbush Securities sold 2,413 Ascendis Pharma A/S shares in Q1 2024, an estimated $304K.
  • Wedbush Securities first reported a position in Ascendis Pharma A/S in Q4 2023 and held it in 1 quarter.
  • Wedbush Securities's Ascendis Pharma A/S position peaked at $304K in Q4 2023.
  • 189 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q1 2024.

Based on Wedbush Securities's 13F filing for Q1 2024, filed 15 May 2024.